Recent events
Recent events tied to this brand in public sources.
Back to profile47 entries · Page 1 of 3
2026
Gilead announces acquisition of PepStar oral inflammation drug program
Gilead said it would acquire PepStar Therapeutics’ oral inflammation drug program for a $1.275 billion cash upfront payment. The program includes an experimental treatment for intestinal disease.
2024
FDA approves expanded pediatric indication for Vemlidy
The US Food and Drug Administration approved Gilead Sciences’ supplemental new drug application for Vemlidy to treat chronic hepatitis B in certain pediatric patients.
2024
Gilead completes acquisition of CymaBay Therapeutics
Gilead Sciences announced that it completed the acquisition of CymaBay Therapeutics for around $4.3 billion. CymaBay now operates as a fully owned Gilead subsidiary, and its common stock is no longer available for trading on Nasdaq.
2024
Gilead discontinues ENHANCE-3 after interim analysis
Gilead discontinued the phase 3 ENHANCE-3 trial of magrolimab with venetoclax and azacitidine after an independent monitoring committee's interim overall-survival analysis found futility and an increased risk of death, mainly driven by respiratory failure and infections. Patients will discontinue magrolimab treatment.
2023
Gilead and Compugen announce exclusive antibody-program license
Gilead Sciences announced an agreement with Compugen to exclusively license Compugen’s pre-clinical antibody program against IL-18 binding protein, including the COM503 drug candidate. Gilead will make an immediate $60 million payment, with potential additional milestone payments and royalties described in the agreement.
2023
Gilead and Assembly Biosciences enter antiviral research partnership
Gilead Sciences and Assembly Biosciences entered into a 12-year partnership to advance research and development of antiviral therapies, initially focused on herpesviruses, hepatitis B virus and hepatitis D virus.
2023
Gilead expands IT partnership with Cognizant
Gilead Sciences expanded its collaboration with Cognizant through a new five-year service agreement worth approximately $800 million. Cognizant will manage Gilead’s global IT infrastructure, platforms, applications and advanced analytics.
2023
Gilead discontinues ENHANCE trial
Gilead Sciences announced the discontinuation of the phase 3 ENHANCE trial evaluating magrolimab plus azacitidine in higher-risk MDS after a planned analysis found the trial futile. The company recommended stopping magrolimab treatment for enrolled patients, and investigators and the company were evaluating next steps for them.
2023
FDA approves expanded Veklury use for patients with severe renal impairment
The U.S. Food and Drug Administration approved a supplemental application for Veklury (remdesivir) to treat COVID-19 patients with severe renal impairment, including patients on dialysis, Gilead Sciences said.
2022
FDA approves Sunlenca for certain adults with HIV-1
The U.S. Food and Drug Administration approved Gilead Sciences' Sunlenca (lenacapavir) for adults living with HIV-1 whose infections cannot be successfully treated with other available treatments because of resistance, intolerance, or safety considerations.
2022
Gilead completes acquisition of MiroBio
Gilead announced that it completed its acquisition of privately held U.K.-based biotechnology company MiroBio for approximately $405 million in cash. The acquisition included MiroBio's discovery platform and portfolio of immune inhibitory receptor agonists.
2022
Düsseldorf court rules Gilead sofosbuvir infringes NuCana patent
NuCana reported that the Regional Court of Düsseldorf issued a judgment that Gilead's sofosbuvir infringes NuCana's European composition-of-matter patent.
2022
Gilead pledges grants for monkeypox education
Gilead Sciences said it planned to provide up to $5 million in grants to help LGBTQ+ and human-rights advocacy groups develop public-health responses to monkeypox. The funds include grants to named groups and emergency grants for smaller organizations worldwide.
2022
Gilead agrees to acquire MiroBio
Medicxi announced that MiroBio had entered into a definitive agreement to be acquired by Gilead Sciences for approximately $405 million in cash, subject to customary adjustments. The acquisition was an agreement, not a reported completion.
2022
Curebase raises $40 million in Series B funding
Curebase announced that it had raised $40 million in Series B funding. Industry Ventures led the round, which included new and existing investors.
2022
Gilead Sciences invests in Curebase to deepen their partnership
As part of Curebase's funding round, Gilead Sciences made a strategic investment to deepen its partnership with Curebase on implementing decentralized and hybrid capabilities in interventional trials.
2022
Gilead unveils pediatric drug development center in Ireland
Gilead Sciences unveiled a new global pediatric drug development center in Dublin, Ireland. The center is slated to conduct pediatric clinical trials for seven products across 18 countries and will have 33 job openings by the end of 2022.
2022
Gilead settles with defendants in PrEP fraud lawsuit
Gilead settled for an undisclosed amount with some key defendants in a lawsuit alleging that they profited illegally from drugs supplied through its charitable program. An attorney for one group of defendants said her clients denied the accusations and settled after the court froze their assets.
2021
Royalty Pharma sues Gilead over royalties
Royalty Pharma Collection Trust sued Gilead Sciences over alleged failure to pay royalties for use of a patent covering emtricitabine. The plaintiffs allege that Gilead used the patented treatment in more than ten drug combinations and breached a royalty-payment contract; these are allegations, not findings stated in the source.
2021
Patients sue Gilead over alleged toxicity and disclosure of HIV drug risks
Patients with HIV brought a civil suit against Gilead, accusing the company of failing to properly report potential health effects of its HIV drugs and alleging that the drugs caused kidney and bone problems. The claims are allegations by the plaintiffs, not a court determination.